Advertisement
A or DHR or TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher Corporation (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) operate in the life sciences tools and diagnostics sector, with overlapping exposure to healthcare research and biopharma spending.
- Recent market activity shows mixed performance across the group, influenced by broader economic sensitivity in capital equipment purchases and upcoming earnings reports.
- TMO reported first-quarter 2026 revenue growth of 6% to $11.01 billion, beating estimates, with its second-quarter results scheduled for release on July 23, 2026.
- Valuation multiples and growth trajectories differ, with each company exhibiting distinct sensitivities to M&A (mergers and acquisitions) activity and organic demand trends.
- Sector-wide sentiment remains tied to pharmaceutical R&D budgets and regulatory environments, creating relative performance contrasts among the three.
- Market positioning highlights trade-offs in scale, diversification, and end-market exposure that investors evaluate when comparing the names.
Introduction
Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) represent established players in the life sciences and analytical instrumentation space. These stocks attract attention from institutional investors, sector specialists, and traders monitoring healthcare supply chains and research spending cycles. The comparison provides a framework for assessing relative performance, business model differences, and positioning within a capital-intensive industry. Market participants seeking to understand sector dynamics, valuation contrasts, and recent momentum often review such peer groups to inform portfolio construction or tactical allocation decisions.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has reflected broader sector volatility tied to capital spending patterns among research institutions and biopharma clients. Performance has been influenced by ongoing demand for its chromatography and mass spectrometry platforms, alongside sensitivity to macroeconomic factors affecting laboratory budgets. Sentiment has remained measured as investors monitor order trends and integration of recent product launches within the company's core segments.
Danaher Corporation (DHR) Overview and Recent Performance
Danaher Corporation (DHR) operates a diversified portfolio that includes life sciences, diagnostics, and environmental solutions through its Danaher Business System operating model. Recent market activity has shown the shares responding to shifts in healthcare utilization and instrumentation demand, with particular attention to its bioprocessing and diagnostics franchises. Performance in recent weeks has been shaped by M&A (mergers and acquisitions) execution and organic growth in key verticals, amid a backdrop of cautious capital deployment by customers. Market observers note the company's scale as a factor in relative stability during periods of sector rotation.
Thermo Fisher Scientific (TMO) Overview and Recent Performance
Thermo Fisher Scientific (TMO) delivers a broad range of life sciences tools, diagnostics, and laboratory services, serving academic, biopharma, and clinical customers. In recent weeks, the stock has traded in a range following its first-quarter 2026 results, which showed revenue rising 6% to $11.01 billion and adjusted earnings per share (EPS) increasing 6% to $5.44. The company is scheduled to report second-quarter results on July 23, 2026, keeping investor focus on organic growth trends and margin dynamics. Broader market activity reflects ongoing evaluation of its scale advantages and exposure to research funding cycles.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots drawn from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance statistics tailored to current market conditions. Only those demonstrating strong suitability and historical metrics earn placement in the trending section. Available bots span a wide range of win rates, drawdowns, and return profiles, allowing users to compare options across different trading styles. The resource provides transparent statistics to help evaluate fit for individual preferences. Review the Trending AI Robots page for the latest selections.
Head-to-Head Comparison
Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) share exposure to life sciences research and diagnostics yet differ in business models and growth drivers. Agilent (A) emphasizes precision analytical tools with higher sensitivity to laboratory capital budgets, while Danaher (DHR) leverages a diversified operating system across multiple end markets, offering potential ballast during sector-specific slowdowns. Thermo Fisher (TMO) benefits from greater scale and integrated offerings, which can support steadier revenue visibility but also heighten valuation sensitivity to earnings beats or misses. Recent momentum has varied, with TMO’s reported first-quarter results providing a near-term reference point amid upcoming updates. Risk factors include common sector exposures to R&D spending fluctuations and regulatory changes, offset by differing degrees of geographic and product diversification. Market sentiment reflects ongoing assessment of these trade-offs in valuation multiples and positioning relative to peers.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative sector positioning in recent market activity, Tickeron’s AI models currently assign a modestly higher probability of favorable near-term characteristics to Thermo Fisher Scientific (TMO). This assessment incorporates its reported first-quarter results and scale advantages, though outcomes remain subject to broader market variables and the upcoming earnings release. The models emphasize probabilistic evaluation rather than deterministic forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- DHR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 3 bearish.
- DHR’s TA Score: 4 bullish, 5 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +5.41% price change this week, while DHR (@Medical Specialties) price change was -6.05% , and TMO (@Medical Specialties) price fluctuated +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
DHR is expected to report earnings on Oct 27, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | TMO | |
| Capitalization | 39.1B | 135B | 211B |
| EBITDA | 1.96B | 7.08B | 11.7B |
| Gain YTD | 2.449 | -15.994 | -1.736 |
| P/E Ratio | 27.83 | 34.14 | 30.58 |
| Revenue | 7.23B | 24.8B | 45.2B |
| Total Cash | 1.81B | N/A | 1.12B |
| Total Debt | 3.36B | 18.5B | 43.2B |
A | DHR | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 20 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 6 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 80 | |
SMR RATING 1..100 | 44 | 80 | 62 | |
PRICE GROWTH RATING 1..100 | 19 | 51 | 40 | |
P/E GROWTH RATING 1..100 | 56 | 72 | 37 | |
SEASONALITY SCORE 1..100 | 75 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (6) in the Medical Specialties industry is in the same range as A (10) in the Biotechnology industry, and is in the same range as TMO (12) in the Medical Specialties industry. This means that DHR's stock grew similarly to A’s and similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as DHR (100) in the Medical Specialties industry, and is in the same range as A (100) in the Biotechnology industry. This means that TMO's stock grew similarly to DHR’s and similarly to A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for DHR (80) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and somewhat faster than DHR’s over the last 12 months.
A's Price Growth Rating (19) in the Biotechnology industry is in the same range as TMO (40) in the Medical Specialties industry, and is in the same range as DHR (51) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and similarly to DHR’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as A (56) in the Biotechnology industry, and is somewhat better than the same rating for DHR (72) in the Medical Specialties industry. This means that TMO's stock grew similarly to A’s and somewhat faster than DHR’s over the last 12 months.
| A | DHR | TMO | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 46% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 61% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 65% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 70% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 64% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 53% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 54% | 3 days ago 61% |
| Declines ODDS (%) | 6 days ago 64% | 5 days ago 61% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 57% | 2 days ago 63% |
| Aroon ODDS (%) | N/A | 2 days ago 54% | 2 days ago 59% |
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.